Volatile conditions in the biopharma funding market and the rise of novel therapies make it imperative that a company’s operating strategies be managed in a way that successfully shepherd assets forward in a cost-efficient manner. For start-up companies with one or two assets, stretching runway to reach the next milestone is top of mind when satisfying investors and securing additional investment. Midsize and larger companies must also marshal resources strategically in their race to get assets into the clinic in a hypercompetitive research environment. Companies can choose to outsource, insource, or defer costs at every stage of R&D and across dozens of different workflows. During this interactive discussion, hear how leaders pursuing novel therapies are weighing their strategies for resourcing to support great science while meeting the practical and economic considerations of R&D.
Event Timeline
6 - 6:45 PM - Panel discussion with Q&A
6:45 - 8 PM - Networking, light refreshments, and tours of SmartLabs 40 Guest St facility
Panel Information
Scaling to the Clinic: Strategies for evaluating the right lab resourcing solution for your R&D efforts
Moderator: Demet Aybar – Founder/Owner at Demet Aybar – US Lab Partners
Panelists:
· Angela Hui, VP of Operations at Elektrofi
· John Maynes, Associate Director of Lab Operations at Prime Medicine
· Christian Lawrence, Site Director at SmartLabs 6 Tide St facility
The event is free to attend, but seating is limited. Please RSVP to reserve your spot today!
